person · Reporting owner
Binder-Scholl Gwendolyn Knowlton
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Chief Technology Officer | January 14, 2019 | January 16, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date January 14, 2019 · Filed January 16, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | Direct | 2,487 |
Reported balance
After 2019-01-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-01-14 · Sale · Disposed 1,514 · Balance 2,487 F1: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,979,951 ordinary shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.
F3: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,979,951 ordinary shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 14, 2019 Filed Jan 16, 2019 21:31 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares representing Ordinary Shares | 1,514 | $5.37 | $8,129.27 |
DisclosureSEC source: 0001104659-19-002166 · a4.xml · nonDerivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,487 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,979,951 ordinary shares of the Issuer. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 19:58 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares | 25,000 | $13.79 | $344,750.00 |
DisclosureSEC source: 0001104659-18-060128 · a4.xml · nonDerivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $13.54 to $13.995, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 20:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | SaleAmerican Depositary Shares | 25,000 | $10.25 | $256,250.00 |
DisclosureSEC source: 0001104659-18-054853 · a4.xml · nonDerivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $10.15 to $10.41, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 17:20 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 96,036 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-002676 · a4.xml · derivative · entry 2 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,036 Underlying: Ordinary Shares · 96,036 shares Expires not disclosed F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F4 · derivative.exercise_date: Exercisable as to 24,009 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 24,009 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022. F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 17:20 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 429,984 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001104659-18-002676 · a4.xml · derivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,984 Underlying: Ordinary Shares · 429,984 shares Expires 2028-01-12 F1 · derivative.exercise_price: The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 107,496 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 8,958 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 17:02 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 2,072,976 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-002826 · a4.xml · derivative · entry 1 Binder-Scholl Gwendolyn Knowlton · CIK 0001662116 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072,976 Underlying: Ordinary Shares · 2,072,976 shares Expires 2027-01-13 F1 · derivative.exercise_price: The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount. F2 · derivative.exercise_date: Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.